Brusilow, SW. Urea cycle disorders: clinical paradigm of hyperammonemic encephalopathy. Prog Liver Dis. 1995;13:293–309.
Caldovic, L, Morizono, H, Panglao, MG, et al.
Late onset N-acetylglutamate synthase deficiency caused by hypomorphic alleles. Hum Mutat. 2005;25:293–8.
Caldovic, L, Morizono, H, Tuchman, M. Mutations and polymorphisms in the human N-acetylglutamate synthase (NAGS) gene. Hum Mutat. 2007;28:754–9.
Brusilow, SW, Maestri, NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr. 1996;43:127–70.
Altarescu, G, Brooks, B, Eldar-Geva, T, et al.
Polar body-based preimplantation genetic diagnosis for N-acetylglutamate synthase deficiency. Fetal Diagn Ther. 2008;24:170–6.
Sniderman King, L, Singh, RH, Rhead, WJ, Smith, W, Lee, B, Summar, ML. Genetic counseling issues in urea cycle disorders. Crit Care Clin. 2005;21:S37–44.
Kamoun, P, Fensom, AH, Shin, YS, et al.
Prenatal diagnosis of the urea cycle diseases: a survey of the European cases. Am J Med Genet. 1995;55:247–50.
Butterworth, RF. Effects of hyperammonaemia on brain function. J Inherit Metab Dis. 1998;21
Tuchman, M, Lee, B, Lichter-Konecki, U, et al.
Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab. 2008;94:397–402.
Tuchman, M, Yudkoff, M. Blood levels of ammonia and nitrogen scavenging amino acids in patients with inherited hyperammonemia. Mol Genet Metab. 1999;66:10–15.
Gropman, A. Brain imaging in urea cycle disorders. Mol Genet Metab
Batshaw, ML, Painter, MJ, Sproul, GT, Schafer, IA, Thomas, GH, Brusilow, S. Therapy of urea cycle enzymopathies: three case studies. Johns Hopkins Med J. 1981;148:34–40.
Batshaw, ML, MacArthur, RB, Tuchman, M.
Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr. 2001;138:S46–54; discussion S54–5.
Ah Mew, N, McCarter, R, Daikhin, Y, Nissim, I, Yudkoff, M, Tuchman, M. N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia. Pediatrics. 2010;126:e208–14.
Ah Mew, N, Payan, I, Daikhin, Y, Nissim, I, Tuchman, M, Yudkoff, M. Effects of a single dose of N-carbamylglutamate on the rate of ureagenesis. Mol Genet Metab. 2009;98:325–30.
Daniotti, M, la Marca, G, Fiorini, P, Filippi, L. New developments in the treatment of hyperammonemia: emerging use of carglumic acid. Int J Gen Med. 2011;4:21–8.
Guffon, N, Vianey-Saban, C, Bourgeois, J, Rabier, D, Colombo, JP, Guibaud, P. A new neonatal case of N-acetylglutamate synthase deficiency treated by carbamylglutamate. J Inherit Metab Dis. 1995;18:61–5.
Caldovic, L, Morizono, H, Daikhin, Y, et al.
Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate. J Pediatr. 2004;145:552–4.
Caldovic, L, Ah Mew, N, Shi, D, Morizono, H, Yudkoff, M, Tuchman, M. N-acetylglutamate synthase: structure, function and defects. Mol Genet Metab. 2010;100
Bachmann, C, Krahenbuhl, S, Colombo, JP, Schubiger, G, Jaggi, KH, Tonz, O. N-acetylglutamate synthetase deficiency: a disorder of ammonia detoxication. N Engl J Med. 1981;304:543.
Bachmann, C, Colombo, JP, Jaggi, K. N-acetylglutamate synthetase (NAGS) deficiency: diagnosis, clinical observations and treatment. Adv Exp Med Biol. 1982;153:39–45.
Tuchman, M, Caldovic, L, Daikhin, Y, et al.
N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr Res. 2008;64:213–17.
Haberle, J, Schmidt, E, Pauli, S, et al.
Mutation analysis in patients with N-acetylglutamate synthase deficiency. Hum Mutat. 2003;21:593–7.
Rogozin, IB, Milanesi, L. Analysis of donor splice sites in different eukaryotic organisms. J Mol Evol. 1997;45:50–9.
Ah Mew, N, Caldovic, L. N-acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment. The Application of Clinical Genetics. 2011;4:127–35.
Haberle, J. Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency. Ther Clin Risk Manag. 2011;7:327–32.
Batshaw, ML, Msall, M, Beaudet, AL, Trojak, J. Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency. J Pediatr. 1986;108:236–41.
Msall, M, Monahan, PS, Chapanis, N, Batshaw, ML. Cognitive development in children with inborn errors of urea synthesis. Acta Paediatr Jpn. 1988;30:435–41.
Uchino, T, Endo, F, Matsuda, I. Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis. 1998;21
Bachmann, C. Long-term outcome of patients with urea cycle disorders and the question of neonatal screening. Eur J Pediatr. 2003;162
Batshaw, ML, Roan, Y, Jung, AL, Rosenberg, LA, Brusilow, SW. Cerebral dysfunction in asymptomatic carriers of ornithine transcarbamylase deficiency. N Engl J Med. 1980;302:482–5.
Gyato, K, Wray, J, Huang, ZJ, Yudkoff, M, Batshaw, ML. Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency. Ann Neurol. 2004;55:80–6.
Gropman, AL, Batshaw, ML. Cognitive outcome in urea cycle disorders. Mol Genet Metab. 2004;81
Corne, C, Fouilhoux, A, Aquaviva, C, Besson, G. First French case of NAGS deficiency. 20 years of follow up. Mol Genet Metab. 2011;102:275.
Gessler, P, Buchal, P, Schwenk, HU, Wermuth, B. Favourable long-term outcome after immediate treatment of neonatal hyperammonemia due to N-acetylglutamate synthase deficiency. Eur J Pediatr. 2010;169:197–9.
Nordenstrom, A, Halldin, M, Hallberg, B, Alm, J. A trial with N-carbamylglutamate may not detect all patients with NAGS deficiency and neonatal onset. J Inherit Metab Dis. 2007;30:400.
Grody, WW, Chang, RJ, Panagiotis, NM, Matz, D, Cederbaum, SD. Menstrual cycle and gonadal steroid effects on symptomatic hyperammonaemia of urea-cycle-based and idiopathic aetiologies. J Inherit Metab Dis. 1994;17:566–74.
Guffon, N, Schiff, M, Cheillan, D, Wermuth, B, Haberle, J, Vianey-Saban, C. Neonatal hyperammonemia: the N-carbamoyl-Lglutamic acid test. J Pediatr. 2005;147:260–62.
Schmidt, E, Nuoffer, JM, Haberle, J, et al.
Identification of novel mutations of the human N-acetylglutamate synthase gene and their functional investigation by expression studies. Biochim Biophys Acta. 2005;1740:54–9.
Belanger-Quintana, A, Martinez-Pardo, M, Garcia, MJ, et al.
Hyperammonaemia as a cause of psychosis in an adolescent. Eur J Pediatr. 2003;162:773–5.
Heckmann, M, Wermuth, B, Haberle, J, Koch, HG, Gortner, L, Kreuder, JG. Misleading diagnosis of partial N-acetylglutamate synthase deficiency based on enzyme measurement corrected by mutation analysis. Acta Paediatr. 2005;94:121–4.
Haberle, J, Denecke, J, Schmidt, E, Koch, HG. Diagnosis of N-acetylglutamate synthase deficiency by use of cultured fibroblasts and avoidance of nonsense-mediated mRNA decay. J Inherit Metab Dis. 2003;26:601–5.
Caldovic, L, Morizono, H, Panglao, MG, Cheng, SF, Packman, S, Tuchman, M. Null mutations in the N-acetylglutamate synthase gene associated with acute neonatal disease and hyperammonemia. Hum Genet. 2003;112:364–8.
Takanashi, J, Barkovich, AJ, Cheng, SF, et al.
Brain MR imaging in neonatal hyperammonemic encephalopathy resulting from proximal urea cycle disorders. Am J Neuroradiol. 2003;24:1184–7.
Elpeleg, O, Shaag, A, Ben-Shalom, E, Schmid, T, Bachmann, C. N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy. Ann Neurol. 2002;52:845–9.
Forget, PP, van Oosterhout, M, Bakker, JA, Wermuth, B, Vles, JS, Spaapen, LJ. Partial N-acetyl-glutamate synthetase deficiency masquerading as a valproic acid-induced Reye-like syndrome. Acta Paediatr. 1999;88:1409–11.
Plecko, B, Erwa, W, Wermuth, B. Partial N-acetylglutamate synthetase deficiency in a 13-year-old girl: diagnosis and response to treatment with N-carbamylglutamate. Eur J Pediatr. 1998;157:996–8.
Morris, AA, Richmond, SW, Oddie, SJ, Pourfarzam, M, Worthington, V, Leonard, JV. N-acetylglutamate synthetase deficiency: favourable experience with carbamylglutamate. J Inherit Metab Dis. 1998;21:867–8.
Hinnie, J, Colombo, JP, Wermuth, B, Dryburgh, FJ. N-Acetylglutamate synthetase deficiency responding to carbamylglutamate. J Inherit Metab Dis. 1997;20:839–40.
Vockley, J, Vockley, CM, Lin, SP, et al.
Normal N-acetylglutamate concentration measured in liver from a new patient with N-acetylglutamate synthetase deficiency: physiologic and biochemical implications. Biochem Med Metab Biol. 1992;47:38–46.
Burlina, AB, Bachmann, C, Wermuth, B, et al.
Partial N-acetylglutamate synthetase deficiency: a new case with uncontrollable movement disorders. J Inherit Metab Dis. 1992;15:395–8.
Pandya, AL, Koch, R, Hommes, FA, Williams, JC. N-acetylglutamate synthetase deficiency: clinical and laboratory observations. J Inherit Metab Dis. 1991;14:685–90.
Elpeleg, ON, Colombo, JP, Amir, N, Bachmann, C, Hurvitz, H. Late-onset form of partial N-acetylglutamate synthetase deficiency. Eur J Pediatr. 1990;149:634–6.
Bachmann, C, Brandis, M, Weissenbarth-Riedel, E, Burghard, R, Colombo, JP. N-acetylglutamate synthetase deficiency, a second patient. J Inherit Metab Dis. 1988;11:191–3.
Schubiger, G, Bachmann, C, Barben, P, Colombo, JP, Tonz, O, Schupbach, D. N-acetylglutamate synthetase deficiency: diagnosis, management and follow-up of a rare disorder of ammonia detoxication. Eur J Pediatr. 1991;150:353–6.